The three PI3K inhibitors, taselisib, copanlisib, and pictilisib, each showed a trend towards association with PI3K mutational status, but this was not statistically significant ( Figure 3A , right panels).
← all excerpts
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines.
1
—
—